<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021047</url>
  </required_header>
  <id_info>
    <org_study_id>010172</org_study_id>
    <secondary_id>NCI-01-C-0172</secondary_id>
    <secondary_id>MB-NAVY-00-07</secondary_id>
    <secondary_id>MB-NAVY-B01-008</secondary_id>
    <secondary_id>CDR0000068741</secondary_id>
    <nct_id>NCT00021047</nct_id>
    <nct_alias>NCT00015743</nct_alias>
  </id_info>
  <brief_title>Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor</brief_title>
  <official_title>A Phase I/II Trial of Epirubicin, Carboplatin &amp; Capecitabine in Adult Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin,&#xD;
      and capecitabine in treating patients who have unresectable locally advanced, metastatic, or&#xD;
      recurrent solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and the recommended phase II dose of capecitabine&#xD;
           administered with epirubicin and carboplatin in patients with unresectable locally&#xD;
           advanced, metastatic, or recurrent solid tumors.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics (PK) of capecitabine and correlate these PK parameters&#xD;
           with clinical toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate end-of-infusion levels of epirubicin and its metabolites with epirubicin dose&#xD;
           and clinical toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the possible correlation between polymorphisms in the promoter region of the&#xD;
           thymidylate synthase gene with clinical toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of capecitabine.&#xD;
&#xD;
      Patients receive epirubicin IV over 2 hours and carboplatin IV over 30 minutes on day 1 and&#xD;
      oral capecitabine twice daily on days 2-5, 8-12, and 15-19. Courses repeat every 4 weeks in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 24 additional&#xD;
      patients are treated at the recommended phase II dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-45 patients (24 patients for phase II) will be accrued for&#xD;
      this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Progressive disease on standard therapy, including:&#xD;
&#xD;
                    -  Locally advanced, unresectable primary or recurrent tumor OR&#xD;
&#xD;
                    -  Metastatic disease&#xD;
&#xD;
          -  Previously untreated metastatic cancer for which study regimen represents reasonable&#xD;
             initial chemotherapy with palliative intent (e.g., metastatic gastric cancer,&#xD;
             hepatobiliary cancer, or cancers for which no effective standard therapy exists)&#xD;
             allowed&#xD;
&#xD;
          -  Phase II portion:&#xD;
&#xD;
               -  Diagnosis of cancer of the upper aerodigestive tract (head and neck, esophagus,&#xD;
                  stomach, or hepatobiliary)&#xD;
&#xD;
               -  No potential curative treatment options including surgery, radiotherapy,&#xD;
                  chemoradiotherapy, or combination chemotherapy&#xD;
&#xD;
               -  No leukemia or lymphoma&#xD;
&#xD;
               -  No primary CNS malignancies or CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No serious concurrent medical illness that would preclude study participation&#xD;
&#xD;
          -  No active infections requiring IV antibiotic therapy&#xD;
&#xD;
          -  No history of allergy to platinum compounds, mannitol, or antiemetics used with study&#xD;
             drugs&#xD;
&#xD;
          -  No history of severe intolerance to fluorouracil&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  No prior cumulative doxorubicin dose of more than 300 mg/m2&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 8 weeks since prior strontium chloride Sr 89&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior sorivudine or brivudine&#xD;
&#xD;
          -  No concurrent sorivudine or brivudine&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian P. Monahan, MD, FACP</last_name>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Szabo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center, Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

